01PREP
Archive Gating
Assess FFPE tissue preservation and intact nuclei to screen eligible retrospective cohorts.
FFPE QC · Nuclei Extraction
✦ 01 / CONTINUOUS WORKFLOW
A continuum of cell-level evidence
Arc·ell seamlessly pairs archival pathology, same-cell multi-omics, and evolutionary analytics so every study unlocks defensible conclusions from retrospective patient histories.
PHILOSOPHYA Defensible Route,
A Defensible Route,
Not a Black Box
Engineered backwards from critical biological questions to preserve cell identity.
The platform addresses the pivotal checkpoints that determine single-cell oncology success: strict archival tissue QC, high-throughput in situ nanowell library preparation, direct same-cell multi-omics pairing, and lineage-aware phylogenetic reconstruction.
CONTINUOUS WORKFLOW
The Arc·ell Continuum
Each module operates independently or combines into an end-to-end evidence trajectory from clinical specimen to published mechanism.
02DNA
Clonal Resolution
Generate high-resolution genome-wide copy number profiles from archival samples via Arc-well.
ARC-WELL · CNA Genomics
03DUAL
Same-Cell Pairing
Read DNA copy number and 3' RNA from the identical microwell using wellDR-seq chemistry.
WELLDR-SEQ · Multi-omics
04INSIGHT
Evolution Trees
Trace tumor phylogenies, clonal seeding, and therapy-resistant subclone dynamics.
ARCELL INSIGHT · Analytics
PROJECT INITIATIONStart with Material,
Start with Material,
End with Mechanism
Before sequencing the first cell, we align on quality gates, cohort inclusion criteria, and mechanistic hypotheses.
Consult Study Design →STEP 01Define Core Hypothesis
Clarify tumor origin, primary-to-metastasis evolution, therapy selection, or genotype-to-phenotype regulation.
STEP 02Match Evidence Modality
Select Arc-well for large-cohort CNA tracking or wellDR-seq for same-cell multi-omics mechanistic depth.
STEP 036–8 Week Pilot Validation
Run a pilot cohort of 3–5 representative specimens with strict gating (GO / HOLD / STOP) to de-risk full study scaling.